Clinical trial

Biomarkers in Diabetic Retinopathy Treated With Faricimab vs Biosimilar Ranibizumab

NCT07520045

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2026-03-12

PhaseNA

Study timeline

Study start (actual)2026-03-12Date precision: day

Registry last updated2026-04-09

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Diabetic Retinopathy (DR)unresolved

Diabetic Macular Edema (DME)unresolved

Interventions

FaricimabDRUG · verified · RxNorm: faricimab

Biosimilar ranibizumabDRUG

Sponsors & collaborators

Osijek University Hospitallead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07520045 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.